Ianalumab clinical trials
Also written VAY736.
ClinicalTrials.gov finds 35 studies for ianalumab. How that becomes 34 here
Every study that search finds has been read, to see whether and how it gives ianalumab. ClinicalTrials.gov counts as of Nov 16, 2026. How drug pages count
- 35Found by its intervention search · See all 35 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 26 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
- 35Give ianalumab to participants
- −1Observe patients on it, or give it outside a trial
- 34Test it: the count on this site
Get an email when these change. Save the ianalumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
33 studies that test it; most in 2022 (6); 1 more planned to start later
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 1 |
| 2017 | 2 |
| 2018 | 4 |
| 2019 | 1 |
| 2022 | 6 |
| 2023 | 6 |
| 2024 | 4 |
| 2025 | 1 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 34 · Other 0
Often tested with
Tested in the same studies.
Iscalimab (2) · LYS-006 (1) · Arumakimig (1) · Remibrutinib (1) · Eltrombopag (1) · Thrombopoietin Receptor Agonist (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 4, 3 in phase 3
Studies that test ianalumab, phase 3 first.
- Mar 2027Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)Phase 3 · Novartis Pharmaceuticals
- Apr 2027Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)Phase 3 · Novartis Pharmaceuticals
- Sep 2027Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus NephritisPhase 3 · Novartis Pharmaceuticals
- Jul 2027A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic SclerosisPhase 2 · Novartis Pharmaceuticals
Studies
Open first, then newest update. How each study uses ianalumab has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.
Testing it · 34
- Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).RecruitingPhase 3Novartis PharmaceuticalsNCT06133972Long-term extension in lupusWritten as IanalumabReport a problem
- Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)RecruitingPhase 3Novartis PharmaceuticalsNCT06711887With or without stopping treatment in lupus nephritisWritten as IanalumabReport a problem
- Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom BurdenRecruitingPhase 3Novartis PharmaceuticalsNCT07621809In Sjögren's disease with high symptom burdenWritten as VAY736Report a problem
- A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)RecruitingPhase 2Novartis PharmaceuticalsNCT07421167With an investigator's choice of TPO receptor agonist in ITPWritten as ianalumabReport a problem
- A Study of Ianalumab in Addition to Eltrombopag in Pediatric Patients With Primary ITP Who Failed Corticosteroids.Not yet recruitingPhase 2Novartis PharmaceuticalsNCT07660172With eltrombopag in children with ITPWritten as IanalumabReport a problem
- Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)Active, not recruitingPhase 3Novartis PharmaceuticalsNCT05653349With first-line steroids in immune thrombocytopenia (VAYHIT1)Written as IanalumabReport a problem
- A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic SclerosisActive, not recruitingPhase 2Novartis PharmaceuticalsNCT06470048In diffuse cutaneous systemic sclerosisWritten as IanalumabReport a problem
- A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed SteroidsActive, not recruitingPhase 3Novartis PharmaceuticalsNCT05653219With eltrombopag in immune thrombocytopenia after steroids (VAYHIT2)Written as IanalumabReport a problem
- A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of TherapiesActive, not recruitingPhase 2Novartis PharmaceuticalsNCT05885555In immune thrombocytopenia after two lines of therapyWritten as IanalumabReport a problem
- Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis SuppurativaCompletedPhase 2Novartis PharmaceuticalsNCT03827798One cohort in hidradenitis suppurativa among several investigational drugsWritten as VAY736Report a problem
- Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus NephritisActive, not recruitingPhase 3Novartis PharmaceuticalsNCT05126277With standard care in active lupus nephritis (SIRIUS-LN)Written as ianalumab s.c. q4wReport a problem
- A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.Active, not recruitingPhase 3Novartis PharmaceuticalsNCT05985915Long-term extension in Sjögren'sWritten as Ianalumab (VAY736)Report a problem
- Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From IanalumabWithdrawnPhase 2Novartis PharmaceuticalsNCT07039422After earlier benefit in ITP and warm AIHAWritten as IanalumabReport a problem
- Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune DiseaseActive, not recruitingPhase 2Novartis PharmaceuticalsNCT06293365Its auto-injector and syringes comparedWritten as VAY736 1ml PFSReport a problem
- Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)Active, not recruitingPhase 3Novartis PharmaceuticalsNCT05624749On standard care in lupus (SIRIUS-SLE 2)Written as ianalumabReport a problem
- Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)Active, not recruitingPhase 3Novartis PharmaceuticalsNCT05639114Two regimens on standard care in lupus (SIRIUS-SLE 1)Written as IanalumabReport a problem
- A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic AnemiaActive, not recruitingPhase 3Novartis PharmaceuticalsNCT05648968In warm autoimmune haemolytic anaemiaWritten as IanalumabReport a problem
- Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's SyndromeCompletedPhase 3Novartis PharmaceuticalsNCT05350072In active Sjögren's syndrome (NEPTUNUS-1)Written as VAY736Report a problem
- Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's SyndromeActive, not recruitingPhase 3Novartis PharmaceuticalsNCT05349214In active Sjögren's syndrome (NEPTUNUS-2)Written as VAY736Report a problem
- Study the Efficacy and Safety of VAY736 and CFZ533 in SLE PatientsCompletedPhase 2Novartis PharmaceuticalsNCT03656562In systemic lupus erythematosusWritten as VAY736Report a problem
See all 34 studies that test ianalumab →
Tested on its own · 25 — no other medicine in its arm
- Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).RecruitingPhase 3Novartis PharmaceuticalsNCT06133972Long-term extension in lupusWritten as IanalumabReport a problem
- Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)RecruitingPhase 3Novartis PharmaceuticalsNCT06711887With or without stopping treatment in lupus nephritisWritten as IanalumabReport a problem
- Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom BurdenRecruitingPhase 3Novartis PharmaceuticalsNCT07621809In Sjögren's disease with high symptom burdenWritten as VAY736Report a problem
- A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic SclerosisActive, not recruitingPhase 2Novartis PharmaceuticalsNCT06470048In diffuse cutaneous systemic sclerosisWritten as IanalumabReport a problem
- A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of TherapiesActive, not recruitingPhase 2Novartis PharmaceuticalsNCT05885555In immune thrombocytopenia after two lines of therapyWritten as IanalumabReport a problem
- Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus NephritisActive, not recruitingPhase 3Novartis PharmaceuticalsNCT05126277With standard care in active lupus nephritis (SIRIUS-LN)Written as ianalumab s.c. q4wReport a problem
- A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.Active, not recruitingPhase 3Novartis PharmaceuticalsNCT05985915Long-term extension in Sjögren'sWritten as Ianalumab (VAY736)Report a problem
- Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From IanalumabWithdrawnPhase 2Novartis PharmaceuticalsNCT07039422After earlier benefit in ITP and warm AIHAWritten as IanalumabReport a problem
- Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune DiseaseActive, not recruitingPhase 2Novartis PharmaceuticalsNCT06293365Its auto-injector and syringes comparedWritten as VAY736 1ml PFSReport a problem
- Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)Active, not recruitingPhase 3Novartis PharmaceuticalsNCT05624749On standard care in lupus (SIRIUS-SLE 2)Written as ianalumabReport a problem
- Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)Active, not recruitingPhase 3Novartis PharmaceuticalsNCT05639114Two regimens on standard care in lupus (SIRIUS-SLE 1)Written as IanalumabReport a problem
- A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic AnemiaActive, not recruitingPhase 3Novartis PharmaceuticalsNCT05648968In warm autoimmune haemolytic anaemiaWritten as IanalumabReport a problem
- Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's SyndromeCompletedPhase 3Novartis PharmaceuticalsNCT05350072In active Sjögren's syndrome (NEPTUNUS-1)Written as VAY736Report a problem
- Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's SyndromeActive, not recruitingPhase 3Novartis PharmaceuticalsNCT05349214In active Sjögren's syndrome (NEPTUNUS-2)Written as VAY736Report a problem
- ADCC Mediated B-Cell dEpletion and BAFF-R BlockadeCompletedPhase 2/3Novartis PharmaceuticalsNCT03217422In autoimmune hepatitis (AMBER)Written as VAY736Report a problem
- Biopsy Based Study to Understand Mechanism of Action of Ianalumab in Salivary Glands and Explore Relationships With Clinical Assessments.CompletedPhase 2Novartis PharmaceuticalsNCT05124925How it works in the salivary glands in Sjögren'sWritten as IanalumabReport a problem
- Study Comparing Two VAY736 Drug Products in Patients With Rheumatoid ArthritisCompletedPhase 1Novartis PharmaceuticalsNCT03574545Two drug products compared in rheumatoid arthritisWritten as ianalumabReport a problem
- Pharmacokinetics Study of Ianalumab in Chinese Participants With Autoimmune DiseasesWithdrawnPhase 1Novartis PharmaceuticalsNCT06411639In Chinese participants with autoimmune diseasesWritten as ianalumabReport a problem
- Safety and Efficacy of VAY736 in Patients With Primary Sjogren's Syndrome (pSS)CompletedPhase 2Novartis PharmaceuticalsNCT02962895Dose finding in primary Sjögren's syndromeWritten as VAY736Report a problem
- Study of Efficacy and Safety of VAY736 in Patients With Pemphigus VulgarisTerminatedPhase 2Novartis PharmaceuticalsNCT01930175In pemphigus vulgarisWritten as VAY736Report a problem
Showing 20 of 25. See all 25 →
Tested with established drugs · 5 — they are given beside it
- Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)Active, not recruitingPhase 3Novartis PharmaceuticalsNCT05653349With first-line steroids in immune thrombocytopenia (VAYHIT1)Written as IanalumabReport a problem
- A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed SteroidsActive, not recruitingPhase 3Novartis PharmaceuticalsNCT05653219With eltrombopag in immune thrombocytopenia after steroids (VAYHIT2)Written as IanalumabReport a problem
- Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin LymphomaTerminatedPhase 1Novartis PharmaceuticalsNCT04903197Alone and with lenalidomide in non-Hodgkin lymphomaWritten as VAY736Report a problem
- VAY736 in Combination With Ibrutinib in Patients With CLL on IbrutinibTerminatedPhase 1Novartis PharmaceuticalsNCT03400176With ibrutinib in CLLWritten as VAY736Report a problem
- Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary FibrosisTerminatedPhase 2Novartis PharmaceuticalsNCT03287414In idiopathic pulmonary fibrosisWritten as VAY736Report a problem
Tested in a combination · 4 — another drug in the study is under test too
- A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)RecruitingPhase 2Novartis PharmaceuticalsNCT07421167With an investigator's choice of TPO receptor agonist in ITPWritten as ianalumabReport a problem
- A Study of Ianalumab in Addition to Eltrombopag in Pediatric Patients With Primary ITP Who Failed Corticosteroids.Not yet recruitingPhase 2Novartis PharmaceuticalsNCT07660172With eltrombopag in children with ITPWritten as IanalumabReport a problem
- Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis SuppurativaCompletedPhase 2Novartis PharmaceuticalsNCT03827798One cohort in hidradenitis suppurativa among several investigational drugsWritten as VAY736Report a problem
- Study the Efficacy and Safety of VAY736 and CFZ533 in SLE PatientsCompletedPhase 2Novartis PharmaceuticalsNCT03656562In systemic lupus erythematosusWritten as VAY736Report a problem
Observed · 1 — patients on it are followed, or it is given outside a trial
Codes
What other systems call ianalumab · ClinicalTrials.gg INT001242
- MeSH (NLM) C000656267ianalumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) ZN2GQ3II96IANALUMABConfirmed FDA, NLM
- NCI Thesaurus C116788IanalumabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000656267 | ianalumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | ZN2GQ3II96 | IANALUMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C116788 | Ianalumab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.